US-based clinical research company N-Power Medicine has partnered with Merck & Co (MSD) to increase access to clinical trials for oncologists and their patients.

The two companies aim to streamline workflow for clinical research and routine care for patients.

The partnership will make use of N-Power Medicine’s real-time registry and point-of-care platform, which integrates technology, AI and embedded research staff.

It will involve implementing multiple trials in the N-Power Medicine Network, which aims to promote greater physician engagement and provide timely access to clinical trials for eligible patients.

As the network expands, the partners aim to extend this model for clinical development to more oncology indications and cancer centres.

MSD Oncology Clinical Development senior vice-president and head Marjorie Green said: “We look forward to collaborating with N-Power Medicine to leverage their new approach to expanding clinical research to more people with cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This provides the opportunity to foster critically needed innovation in the cancer care ecosystem with the potential to benefit patients in urgent need of new therapies.”

N-Power co-founder and CEO Mark Lee said: “We are proud to collaborate with MSD, a company that is leading innovation in the clinical development process and the acceleration of transformative medicines to people living with cancer.

“This agreement underscores our commitment to partner with oncology clinics to bring the resources and reinvented framework that are needed to meaningfully expand access to more inclusive clinical research.”

The partnership comes after N-Power Medicine secured funds in a Series B round, raising its total financing to date to $72m.

Merck Global Health Innovation Fund led the round, which included contributions from an undisclosed US-based healthcare investor.

N-Power Medicine will use these funds to expand its network of oncology clinics and collaborations with biopharmaceutical companies.

The company’s platform is designed to integrate clinical research into everyday patient care.